Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06569706
Recruiting Not applicable

Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer

NCT06569706 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-10-18
Last updated
2026-01-05

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Nipple-Sparing Mastectomy, with immediate breast reconstruction

Nipple-Sparing Mastectomy, with immediate breast reconstruction: It is an endoscopic approach for mastectomy using an axillary single port

Study summary

Nipple -Sparing Mastectomy (NSM), with immediate breast reconstruction (IBR) can be offered to patients requiring mastectomy when the lesion is more than 2cm from the nipple. Endoscopic mastectomy is a technical alternative for small-volume breasts (cup sizes A, B, C), offering a NSM with IBR, but also concealing the scar on the axillary line. It can be performed with traditional laparoscopic equipment, making this technique much more accessible and less costly than robotic mastectomy. It uses a single-port device that is significantly less costly than robotic equipment.

Feasibility and safety studies remain limited to the Asian continent, and it would undoubtedly be beneficial to initiate research in Europe to add this new technical option to our surgical arsenal. This study project aims to explore the feasibility and safety of endoscopic nipple-sparing mastectomy for breast cancer indications in a French center.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Women between 20 and 75 years. * Patient with an indication for curative mastectomy, either unilateral or bilateral, with nipple preservation: * Extensive Carcinoma In Situ (CIS), more than 2 cm from the nipple * Multicentric Infiltrating Carcinoma (IC), more than 2 cm from the nipple * Large volume Infiltrating Carcinoma, more than 2 cm from the nipple * IC or CIS for which the patient refuses conservative treatment, more than 2 cm from the nipple * Breast volumes: cup sizes A, B, or C as defined by underwear size, and glandular ptosis not exceeding grade 2 according to Regnault's classification * Patient wishing to undergo immediate breast reconstruction. * WHO/OMS (World Health Organization/Organisation Mondiale de la Santé) performance status \<3 Exclusion Criteria: * Cutaneous carcinoma * Inflammatory breast * History of oncological breast surgery on the same breast * Patient who has received radiation treatment on the same breast * Breast hypertrophy requiring a nipple-bearing flap * Smoking ≥ 10 cigarettes/day * BMI \> 35 * Protected patient or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP). * Patient participating in another interventional clinical study. * ASA (physical status score of the American Society of Anesthesiologists) \>2. * Pregnant or breastfeeding women according to Article L1121-5 of the CSP. * Vulnerable persons (those receiving psychiatric care, those deprived of liberty, and those admitted to a health or social institution) according to Article L1121-6 of the CSP. * Absence of effective contraception for patients of childbearing age. * Absence of affiliation with a social security scheme. * Absence of collected free, informed, and written consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Uhmontpellier Montpellier France Recruiting

More University Hospital, Montpellier trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06569706 on ClinicalTrials.gov ↗ ← All trials in France